State Board of Administration of Florida Retirement System increased its stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) by 8.0% during the second quarter, Holdings Channel reports. The fund owned 22,819 shares of the biopharmaceutical company’s stock after buying an additional 1,693 shares during the period. State Board of Administration of Florida Retirement System owned about 0.06% of Clovis Oncology worth $313,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Fox Run Management L.L.C. bought a new position in shares of Clovis Oncology during the second quarter valued at approximately $154,000. CIBC World Markets Inc. increased its position in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 850 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Clovis Oncology during the first quarter valued at about $233,000. Kazazian Asset Management LLC acquired a new position in Clovis Oncology during the first quarter valued at about $282,000. Finally, DekaBank Deutsche Girozentrale increased its position in Clovis Oncology by 38.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 22,800 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 6,300 shares during the last quarter. 98.46% of the stock is owned by institutional investors and hedge funds.
Shares of Clovis Oncology Inc. (NASDAQ:CLVS) traded down 2.96% on Friday, hitting $32.14. 506,673 shares of the stock were exchanged. The company has a 50-day moving average price of $30.85 and a 200 day moving average price of $19.07. Clovis Oncology Inc. has a 12 month low of $11.57 and a 12 month high of $109.18. The company’s market cap is $1.24 billion.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.13) by $0.06. During the same quarter in the prior year, the business earned ($2.10) EPS. Equities analysts forecast that Clovis Oncology Inc. will post ($9.25) EPS for the current fiscal year.
Several equities analysts have recently issued reports on CLVS shares. SunTrust Banks Inc. raised their price target on shares of Clovis Oncology from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, September 23rd. Piper Jaffray Cos. reaffirmed a “neutral” rating and set a $42.00 price target on shares of Clovis Oncology in a research note on Wednesday. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 4th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $41.00 price target on shares of Clovis Oncology in a research note on Monday. Finally, Janney Montgomery Scott downgraded shares of Clovis Oncology from a “buy” rating to a “neutral” rating and raised their price target for the company from $35.00 to $36.00 in a research note on Wednesday, September 21st. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Buy” and a consensus price target of $36.39.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.